Search Results for:
-
LIGAND SIGNS $44M DEAL WITH AHP FOR WOMEN'S HEALTH
The second major part of the agreement, Stein said, is that Ligand gets access to the Wyeth-Ayerst library to search for non-estrogen and non- progesterone receptor targets and choose up to 24 compounds for drug developmentBioWorld Today | Thursday, September 8, 1994 -
FIAU SUITS CHALLENGE IMMUNITY OF CLINICAL RESEARCHERS
and could increase the costs of drug developmentBioWorld Today | Thursday, September 8, 1994 -
NIH TECHNOLOGY LICENSING OPPORTUNITIES TROPICAL JUNGLES YIELD TWO MORE
The calanolides," Boyd wrote, "provide a novel new anti-HIV chemotype for drug developmentBioWorld Today | Tuesday, August 30, 1994 -
OXFORD MOLECULAR, INTELLIGENETICS MERGE SOFTWARE CAPABILITIES
Craig Tyler, Oxford Molecular's marketing manager at the company's Springfield, Va., office, told BioWorld, "Oxford Molecular works at the front end of drug development with software to understand how drugs interact with proteinsBioWorld Today | Friday, August 26, 1994 -
CRYSTALLOGRAPHERS MAP `THE KEY' BLOOD-CLOTTING FACTOR
Now that our crystallographers have solved its molecular structure, it provides the structural design for pharmaceutical drug developmentBioWorld Today | Thursday, August 25, 1994 -
ICOS ATTEMPTING TO RAISE $25M THROUGH STOCK SALE
Proceeds will be used to fund Icos' primary drug development programs for treatment of chronic inflammatory diseases, such as asthma, multiple sclerosis, rheumatoid arthritis and cardiovascular disordersBioWorld Today | Friday, August 19, 1994 -
A NEW ASSIGNMENT FOR RU 486 GENE THERAPISTS SWITCH TRANSGENES ON, OFF
That enabled us to circumvent some time-consuming and costly new-drug development stepsBioWorld Today | Thursday, August 18, 1994 -
IS IT TIME TO BUY BIOTECH?
Wilson said that while the industry has had a string of bona fide clinical trial disasters this year, Wall Street has often overreacted due to its ignorance about the nuts and bolts of the drug development process...Drug development _ what Wilson calls a "black art" _ has become transparent in the biotechnology industryBioWorld Today | Monday, August 15, 1994 -
10TH INTERNATIONAL CONFERENCE ON AIDS TUBERCULOSIS REGIMEN MAY PROVIDE
Toward that end, the Inter-Company Collaboration for AIDS Drug Development, a new organization of U.SBioWorld Today | Wednesday, August 10, 1994 -
CLINTON PLEDGES SUPPORT FOR BASIC RESEARCH
At a June meeting of the National Task Force on AIDS Drug Development, one AIDS activist who interviewed scientists conducting basic research on AIDS found that they spend 30 percent of their time writing grant proposalsBioWorld Today | Friday, August 5, 1994 -
CYTEL STARTS PHASE II OF CYLEXIN
Richard Rose, Cylexin's vice president, drug development and chief medical officer, told BioWorld that only three "mild and reversible" side effects _ two at the injection site and one headache _ possibly related to the drug were seen in Phase I testing, which involved 24 patientsBioWorld Today | Thursday, August 4, 1994 -
OTHER NEWS TO NOTE
company that manufactures HCV immunoassays for Organon. - Macrochem Corp., of Lexington, Mass., has completed the first phase of its drug development collaboration with Dermik Laboratories Inc. - Diatech Inc., of Londonderry, N.H., has signed a deal with Adcock Ingram for the South African rights to Diatech's imaging agentsBioWorld Today | Wednesday, August 3, 1994 -
BRISTOL-MYERS LICENSES ENZON'S SCA TECHNOLOGY
The New York-based company now can use the SCA technology in all areas of drug developmentBioWorld Today | Tuesday, August 2, 1994 -
SEQUANA SIGNS FIRST MAJOR CORPORATE ALLIANCE WITH GLAXO
has signed a five-year research and drug development agreement with the London-based Glaxo Holdings plc to identify genes involved in Type II diabetes or non-insulin dependent diabetes mellitusBioWorld Today | Friday, July 29, 1994 -
CANTAB SIGNS RESEARCH AGREEMENT WITH STANFORD
Cantab Pharmaceuticals plc is collaborating with Stanford University researchers on a drug development program based on regulation of activated T cells, which are linked to a broad range of autoimmune and inflammatory diseasesBioWorld Today | Wednesday, July 27, 1994 -
WASHINGTON NEWS BRIEFS ZOON GIVES UPDATE ONUSER FEE PROGRAM
Volberding cited Indianapolis-based Eli Lilly & Co.'s recent decision to drop all active programs in AIDS drug development as typical of current sentiment in the pharmaceutical industry...Volberding blamed the decline in AIDS drug development on uncertainty over health care reform and the politics of AIDSBioWorld Today | Tuesday, July 26, 1994 -
NIH PROPOSES RULES FOR POTENTIAL CONFLICT OF INTEREST IN RESEARCH
Richard Rose, vice president for drug development at Cytel, in San Diego, also reacted favorablyBioWorld Today | Monday, July 25, 1994 -
BIOTECH EXECUTIVES DESCEND ON CAPITOL HILL
Rubin said the implied task - educating the public about the real risks and benefits of the drug development process and the biotechnology industry's precarious existence - is a daunting oneBioWorld Today | Thursday, July 21, 1994 -
AIDS GROUP WANTS TO CUT RED TAPE IN REVIEW OF RESEARCH PROTOCOLS
The National Task Force on AIDS Drug Development (NTFADD) recommended on Tuesday that regulatory review of research protocols involving human gene transfer be streamlined...These changes, if implemented, could allow gene therapy research and development to achieve parity with traditional drug developmentBioWorld Today | Wednesday, July 20, 1994 -
SYNERGEN ANTRIL TRIALS FOR SEPSIS END IN FAILURE
Carol Werther, an analyst with Cowen & Co., of Boston, added that the failure of Antril highlights, once again, the risks in drug developmentBioWorld Today | Tuesday, July 19, 1994
Category
Current Filters
- xdrug development
Related Keywords
Categories
- x BioWorld Today (2526)
- x BioWorld International (620)
- x BioWorld Insight (356)
- x Bio Perspectives (145)
- x BioWorld Genomics Review (91)
- x State of the Industry Report (58)
- x Top 25 Drug Report (38)
- x BioWorld Snapshots (29)
- x RNAi Report (11)
- x Biotech Innovations (10)
- x Market-Leading Biotech Drugs (4)
- x Executive Compensation Report (3)
- x Recorded (2)
- x Featured (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.